Alberta Drake, Pharm D
About Alberta Drake, Pharm D
Current Position at Bristol Myers Squibb
Alberta Drake serves as the Associate Director for WW Cell Therapy Commercialization Analytics at Bristol Myers Squibb in Madison, New Jersey. In this role, she contributes to the global commercialization strategies for cell therapy, leveraging her extensive background in analytics and market insights within the oncology sector.
Previous Roles at Bristol Myers Squibb
Prior to her current role, Alberta Drake held the position of Senior Manager, Cell Therapy Customer & Market Insights at Bristol Myers Squibb. From 2022 to 2024, she worked in Summit, New Jersey, where she focused on gathering and analyzing customer and market data to support the company's cell therapy division. Earlier, she also served as a Clinical Trial Associate from 2017 to 2018, gaining foundational experience in clinical trial management in Lawrenceville, NJ.
Experience in Oncology Insights and Marketing
Alberta Drake has substantial experience in oncology insights and marketing. From 2020 to 2022, she worked at Daiichi Sankyo, Inc. in Basking Ridge, New Jersey, where she was involved in Global Oncology Insights, Analytics, and Competitive Intelligence. She also contributed to the global marketing efforts for ENHERTU, a prominent oncology drug, demonstrating her expertise in competitive intelligence and marketing strategies.
Academic Contributions at Rutgers University
From 2020 to 2022, Alberta Drake served as an Adjunct Faculty at Rutgers University in New Brunswick, New Jersey. During this period, she contributed to the academic community by sharing her industry experience and insights, thus playing a pivotal role in educating upcoming professionals in the pharmaceutical field.
Educational Background
Alberta Drake holds both a Doctor of Pharmacy (Pharm.D.) and a Master of Business Administration (MBA) from Rutgers University. She earned her Pharm.D. between 2014 and 2020, laying a strong foundation in pharmacy practice. She later pursued an MBA from Rutgers Business School from 2020 to 2023, equipping her with advanced business management skills relevant to her roles in the pharmaceutical industry.